Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
– Sell
-20,600
Closed -$4K – 3400
2022
Q1
$4K Buy
+20,600
New +$3.47M ﹤0.01% 3343
2021
Q4
– Sell
-20,600
Closed -$8K – 3379
2021
Q3
$8K Buy
+20,600
New +$7.6M ﹤0.01% 3336

Other funds holding MRNA

Nuveen's MRNA Position: Q2 2026 in Review

Nuveen reduced its Moderna (MRNA) stake by 29% in Q2 2026, selling an estimated $16.3M and leaving 762,777 shares worth $53.4M. The position accounts for 0.01% of the portfolio, ranked #670.

Nuveen first reported a position in MRNA in Q2 2019 and has held it in 29 quarters since. The position peaked at $490M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Nuveen held 762,777 shares of Moderna worth $53.4M as of Q2 2026.
  • Nuveen sold 315,417 Moderna shares in Q2 2026, an estimated $16.3M.
  • Moderna made up 0.01% of Nuveen's portfolio in Q2 2026, its #670 holding.
  • Nuveen first reported a position in Moderna in Q2 2019 and has held it in 29 quarters since.
  • Nuveen's Moderna position peaked at $490M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.